The estimated Net Worth of Antony C. Mattessich is at least $7.36 millió dollars as of 3 February 2024. Mr. Mattessich owns over 19,642 units of Ocular Therapeutix Inc stock worth over $4,968,636 and over the last 7 years he sold OCUL stock worth over $269,630. In addition, he makes $2,126,150 as President, Chief Executive Officer és Director at Ocular Therapeutix Inc.
Antony has made over 9 trades of the Ocular Therapeutix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 19,642 units of OCUL stock worth $95,460 on 3 February 2024.
The largest trade he's ever made was buying 40,000 units of Ocular Therapeutix Inc stock on 6 June 2019 worth over $112,400. On average, Antony trades about 10,441 units every 140 days since 2017. As of 3 February 2024 he still owns at least 588,701 units of Ocular Therapeutix Inc stock.
You can see the complete history of Mr. Mattessich stock trades at the bottom of the page.
Antony Charles Mattessich serves as President, Chief Executive Officer, Director of the Company. Mr. Mattessich has served as our President and Chief Executive Officer since July 2017 and as a member of our board of directors since June 2017. Mr. Mattessich previously served as Managing Director of Mundipharma International, a therapeutics company, from May 2011 until July 2017. Prior to serving as Managing Director, Mr. Mattessich served in variety of other roles at Mundipharma, including as Head of Western Europe from January 2009 to May 2011 and Managing Director of Napp Pharmaceutical Group, a pharmaceutical company and an independent associated company of Mundipharma, from 2005 until January 2009. Prior to joining Mundipharma International, he served as Therapeutic Franchise Head of Novartis AG, a pharmaceutical company. Mr. Mattessich holds a B.A. in Special Studies from the University of California at Berkeley and an M.I.A. from Columbia University.
As the President, Chief Executive Officer és Director of Ocular Therapeutix Inc, the total compensation of Antony Mattessich at Ocular Therapeutix Inc is $2,126,150. There are no executives at Ocular Therapeutix Inc getting paid more.
Antony Mattessich is 53, he's been the President, Chief Executive Officer és Director of Ocular Therapeutix Inc since 2017. There are 11 older and 4 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
Antony's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 24 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer és Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: